Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 1,000

Just eat it: A review of CD47 and SIRP-α antagonism
Oronsky, B. T., Carter, C. A., Reid, T. R., Brinkhaus, F., & Knox, S. J. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.009 · Cited by 93
Protein nanoparticles directed cancer imaging and therapy
Miao, Y., Yang, T., Yang, S., Yang, M., & Mao, C. (2022) · Nano Convergence · doi:10.1186/s40580-021-00293-4 · Cited by 90
“5 Immunotherapy There are many types of tumor immunotherapy, but most of them exert their anti-tumor effect through T cells in essence [167].”
Background
The bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections
Merani, S., Chen, W., & Elahi, S. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1832 · Cited by 89
“Blocking the immune inhibitory checkpoint pathways such as PD-1 and CTLA-4 recently emerged as “game changing” in cancer immunotherapy [90].”
Background
Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
Westdorp, H., Sköld, A. E., Snijer, B. A., Franik, S., Mulder, S. F., Major, P. P., Foley, R., Gerritsen, W. R., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00191 · Cited by 92
“More recently, cancer immunotherapy hit a new peak, Science Magazine elected cancer immunotherapy the breakthrough of 2013 (7).”
Background
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
Magee, M. S., Kraft, C. L., Abraham, T. S., Baybutt, T. R., Marszalowicz, G. P., Li, P., Waldman, S. A., & Snook, A. E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1227897 · Cited by 88
Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy
He, M., Yang, T., Wang, Y., Wang, M., Chen, X., Ding, D., Zheng, Y., & Chen, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002104 · Cited by 92
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer
Wang, M., Li, Y., Wang, M., Liu, K., Hoover, A. R., Li, M., Towner, R. A., Mukherjee, P., Zhou, F., Qu, J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.10.048 · Cited by 87
The role of immunonutritional support in cancer treatment: Current evidence
Prieto, I., Montemuiño, S., Luna, J., de Torres, M. V., & Amaya, E. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.11.015 · Cited by 87
Cardiovascular Complications Associated With Novel Cancer Immunotherapies
Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0532-8 · Cited by 87
Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation
Zhou, J., Qu, Z., Sun, F., Han, L., Li, L., Yan, S., Stabile, L. P., Chen, L., Siegfried, J. M., & Xiao, G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0073 · Cited by 87
“Discussion Breakthroughs in cancer immunotherapy are inspiring expectations for widespread successes in cancer treatment (44).”
Background
Carbohydrate‐based vaccines for oncotherapy
Wei, M., Wang, Y., & Ye, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21493 · Cited by 86
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A. F., de Jong, F. A., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14289 · Cited by 82
“Trojan Horse” Salmonella Enabling Tumor Homing of Silver Nanoparticles via Neutrophil Infiltration for Synergistic Tumor Therapy and Enhanced Biosafety
Mi, Z., Guo, L., Liu, P., Qi, Y., Feng, Z., Liu, J., He, Z., Yang, X. H., Jiang, S., Wu, J., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c03811 · Cited by 84
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
Chen, C., Gu, Y., Zhang, F., Zhang, Z.-C., Zhang, Y., He, Y.-D., Wang, L., Zhou, N., Tang, F., Liu, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1901434 · Cited by 88
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 88
Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2Kb and H-2Db-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma
Zhuang, X., Wu, T., Zhao, Y., Hu, X., Bao, Y., Guo, Y., Song, Q., Li, G., Tan, S., & Zhang, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.035 · Cited by 84
Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy
Zhang, Z., Yu, X., Wang, Z., Wu, P., & Huang, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.002 · Cited by 84
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 86
Antigen-specific immunotherapies in rheumatic diseases
Pozsgay, J., Szekanecz, Z., & Sármay, G. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.107 · Cited by 85
Engineered biomaterials for cancer immunotherapy
Cai, L., Xu, J., Yang, Z., Tong, R., Dong, Z., Wang, C., & Leong, K. W. (2020) · MedComm · doi:10.1002/mco2.8 · Cited by 83
Uncoupling protein 2 and metabolic diseases
Sreedhar, A., & Zhao, Y. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.03.005 · Cited by 83
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope–Modified DNA Vaccine Immunization
Rekoske, B. T., Smith, H. A., Olson, B. M., Maricque, B. B., & McNeel, D. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0206 · Cited by 81
“), the journal Science named cancer immunotherapy as its "Breakthrough of the Year" for 2013 (6).”
Background
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens
Hebeisen, M., Allard, M., Gannon, P. O., Schmidt, J., Speiser, D. E., & Rufer, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00582 · Cited by 85
“Several strategies have been developed over the last two decades to exploit the therapeutic potential of T cells (6).”
Background
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
Pentcheva‐Hoang, T., Simpson, T. R., Montalvo-Ortiz, W., & Allison, J. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0104 · Cited by 79
“in the cancer-fighting arsenal that was recently named "breakthrough" of the year by Sciencemagazine (22).”
Background
Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration
Liu, J., Meng, H., Nie, S., Sun, Y., Jiang, P., Li, S., Yang, J., Sun, R., & Cheng, W. (2020) · Genomics · doi:10.1016/j.ygeno.2020.08.027 · Cited by 80
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer Immunotherapy
Liu, B., Yang, Y. P., Chao, Y., Xiao, Z., Xu, J., Wang, C., Dong, Z., Hou, L., Li, Q., & Liu, Z. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02582 · Cited by 80
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Wang, Z., Guo, Y., & Han, W. (2017) · Protein & Cell · doi:10.1007/s13238-017-0400-z · Cited by 83
“…al., 1999; Kantoff et al., 2010) and reached an important turnover in the history of cancer treatment as named by Science magazine the “breakthrough of 2013” due to the striking proof-of-concept data of immune checkpoint anti-CTLA-4 and PD-1 antibodies as well as CAR therapy (Couzin-Frankel, 2013).”
Background
Extended O-GlcNAc on HLA Class-I-Bound Peptides
Marino, F., Bern, M. W., Mommen, G. P. M., Leney, A. C., den Brink, J. A. M. V. G.-V., Bonvin, A. M. J. J., Becker, C. H., van Els, C. A. C. M., & Heck, A. J. R. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06586 · Cited by 78
Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy
Han, S., Huang, K., Gu, Z., & Wu, J. (2019) · Nanoscale · doi:10.1039/c9nr08086d · Cited by 85
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 82
“Although anti-cancer immunity and cancer immunotherapy have recently attracted attention [82], cancer immunotherapy has been administered for a long time.”
Background
Targeting monoamine oxidase A for T cell–based cancer immunotherapy
Wang, X., Li, B., Kim, K. G., Wang, Y.-C., Li, Z., Yu, J., Zeng, S., Ma, X., Choi, I. Y., Biase, S. D., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abh2383 · Cited by 82
Synthetic biology in cell-based cancer immunotherapy
Chakravarti, D., & Wong, W. W. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.05.001 · Cited by 80
Robust Antitumor Effects of Combined Anti–CD4-Depleting Antibody and Anti–PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
Ueha, S., Yokochi, S., Ishiwata, Y., Ogiwara, H., Chand, K., Nakajima, T., Hachiga, K., Shichino, S., Terashima, Y., Toda, E., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0190 · Cited by 79
Surface‐Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy
Sun, X., Han, X., Xu, L., Gao, M., Xu, J., Yang, R., & Liu, Z. (2017) · Small · doi:10.1002/smll.201701864 · Cited by 79
GSH‐Responsive Metal–Organic Framework for Intratumoral Release of NO and IDO Inhibitor to Enhance Antitumor Immunotherapy
Du, L., He, H., Xiao, Z., Xiao, H. P., An, Y., Zhong, H., Lin, M., Meng, X., Han, S., & Shuai, X. (2022) · Small · doi:10.1002/smll.202107732 · Cited by 78
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer
Rocca, C., Soda, T., Francesco, E. M. D., Fiorillo, M., Moccia, F. D., Viglietto, G., Angelone, T., & Amodio, N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04498-5 · Cited by 84
Interleukin-15 in the treatment of cancer
Waldmann, T. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.973856 · Cited by 78
“Over the past decade, immunotherapy has joined surgery, radiation therapy and chemotherapy as a pivotal element in the treatment of cancer [1].”
Background
High expression of CD47 in triple negative breast cancer is associated with epithelial‑mesenchymal transition and poor prognosis
Yuan, J., Shi, X., Chen, C., He, H., Liu, L., Wu, J., & Yan, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.10618 · Cited by 77
Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
Yuan, C., Liu, Z., Yu, Q., Wang, X., Bian, M., Yu, Z., & Yu, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50898-3 · Cited by 78
Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy
Li, X., Cai, X., Zhang, Z., Ding, Y., Ma, R., Huang, F., Liu, Y., Liu, J., & Shi, L. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01230 · Cited by 77
Photodynamic Modulation of Endoplasmic Reticulum and Mitochondria Network Boosted Cancer Immunotherapy
Wang, X., Qian, J., Yang, Z., Song, Y., Pan, W., Ye, Y., Qin, X., Yan, X., Huang, X., Wang, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202310964 · Cited by 80
Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
Zhang, W., Xu, L., Cui, P., Piao, C., Xiao, M., Liu, X., Wang, Y., Wu, X., Liu, J., & Yang, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2257-2 · Cited by 77
In Situ Manipulation of Dendritic Cells by an Autophagy-Regulative Nanoactivator Enables Effective Cancer Immunotherapy
Wang, Y., Lin, Y., Wang, J., Qiao, S., Liu, Y., Dong, W., Wang, J., An, H., Yang, C., Mamuti, M., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00143 · Cited by 77
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy
Shang, Q., Dong, Y., Su, Y., Leslie, F., Sun, M., & Wang, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114308 · Cited by 74
Multifunctional platinum‐based nanoparticles for biomedical applications
Cheng, Q., & Liu, Y. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1410 · Cited by 79
Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs
Wang, C., Sun, W., Ye, Y., Bomba, H. N., & Gu, Z. (2017) · Theranostics · doi:10.7150/thno.19017 · Cited by 77
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
Voeller, J., & Sondel, P. M. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001369 · Cited by 77
“1 Research in the field continues to expand exponentially, harnessing the ability of immunotherapy to: (1) enable tumor-selective killing; (2) minimize patient harm by avoiding immune recognition of normal tissues; and (3) achieve complete and long-lasting cures by using the immune system to eradicate identifiable can…”
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
Vitiello, G. A., Bowler, T. G., Liu, M., Medina, B. D., Zhang, J. Q., Param, N. J., Loo, J. K., Goldfeder, R. L., Chibon, F., Rossi, F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124108 · Cited by 78
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Zimmer, L., Eigentler, T., Kiecker, F., Simon, J. C., Utikal, J. S., Mohr, P., Berking, C., Kämpgen, E., Dippel, E., Stadler, R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0716-5 · Cited by 74
A Validated Mathematical Model of Tumor Growth Including Tumor–Host Interaction, Cell-Mediated Immune Response and Chemotherapy
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2014) · Bulletin of Mathematical Biology · doi:10.1007/s11538-014-0037-5 · Cited by 76
“The importance of the immune system fighting the growth of tumors is undeniable, to the point that immunotherapy is lately focusing major attention of cancer therapists and researchers (Couzin-Frankel 2013).”
Background
Anti-GD2 MABS and Next-Generation mAb-Based Agents for Cancer Therapy
Horta, Z. P., Goldberg, J. L., & Sondel, P. M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0021 · Cited by 74
Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Liu, J., Blake, S. J., Smyth, M. J., & Teng, M. W. L. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.18 · Cited by 72
TCR-like antibodies in cancer immunotherapy
He, Q., Liu, Z., Liu, Z., Lai, Y., Zhou, X., & Weng, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0788-4 · Cited by 78
Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product
Jha, B. S., Farnoodian, M., & Bharti, K. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0242 · Cited by 73
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
Pichler, R., Gruenbacher, G., Čulig, Z., Brunner, A., Fuchs, D., Fritz, J., Gander, H., Rahm, A., & Thurnher, M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1945-z · Cited by 73
“After decades of skepticism, immunotherapy is poised to become a mainstay of cancer treatment [1].”
Background
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
Sharabi, A. B., Tran, P. T., Lim, M. K., Drake, C. G., & DeWeese, T. L. (2015) · PubMed · Cited by 72
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover, S., Dougan, M. L., Tyan, K., Giobbie‐Hurder, A., Blum, S. M., Ishizuka, J. J., Qazi, T., Elias, R., Vora, K. B., Ruan, A. B., et al. (2020) · Cancer · doi:10.1002/cncr.32966 · Cited by 77
Immunotherapy in head and neck cancer: aiming at EXTREME precision
Szturz, P., & Vermorken, J. B. (2017) · BMC Medicine · doi:10.1186/s12916-017-0879-4 · Cited by 73
Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value
Li, K., Guo, Q., Zhang, X., Dong, X., Liu, W., Zhang, A., Li, Y., Yan, J., Jia, G., Zheng, Z., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13389 · Cited by 71
Depleting Tumor-Associated Tregs Via Nanoparticle-Mediated Hyperthermia to Enhance Anti-CTLA-4 Immunotherapy
Chen, H., Luan, X., Paholak, H. J., Burnett, J., Stevers, N. O., Sansanaphongpricha, K., He, M., Chang, A. E., Li, Q., & Sun, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0190 · Cited by 71
Recent advances in co-delivery nanosystems for synergistic action in cancer treatment
de Carvalho, B. G., Vit, F. F., Carvalho, H. F., Han, S. W., & de la Torre, L. G. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02168g · Cited by 74
Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy
Mao, L., Ma, P., Luo, X., Cheng, H., Wang, Z., Ye, E., Loh, X. J., Wu, Y., & Li, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c02273 · Cited by 73
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer
Minnar, C. M., Sckisel, G. D., Proia, D. A., Mirsoian, A., Grossenbacher, S. K., Pai, C.-C. S., Chen, M., Monjazeb, A. M., Kelly, K. L., Blazar, B. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1075114 · Cited by 73
High IDO ‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
Seeber, A., Klinglmair, G., Fritz, J., Steinkohl, F., Zimmer, K., Aigner, F., Horninger, W., Gastl, G. A., Zelger, B. G., Brunner, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13560 · Cited by 74
Cancer vaccines: past, present and future; a review article
Grimmett, E., Al-Share, B. A., Alkassab, M. B., Zhou, R. W., Desai, A., Rahim, M. M. A., & Woldie, I. (2022) · Discover Oncology · doi:10.1007/s12672-022-00491-4 · Cited by 77
PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway
Wang, F., Yang, L., Xiao, M., Zhang, Z., Shen, J., Anuchapreeda, S., Tima, S., Chiampanichayakul, S., & Xiao, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-15020-0 · Cited by 73
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
Tan, S., Zhang, C. W.-H., & Gao, G. F. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.29 · Cited by 76
Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology
Valdés‐Mora, F., Handler, K., Law, A. M. K., Salomon, R., Oakes, S. R., Ormandy, C. J., & Gallego‐Ortega, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02582 · Cited by 69
Targeting the tumor microenvironment to enhance antitumor immune responses
der Jeught, K. V., Bialkowski, L., Daszkiewicz, L., Broos, K., Goyvaerts, C., Renmans, D., Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2014) · Oncotarget · doi:10.18632/oncotarget.3204 · Cited by 70
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
on behalf of the Cancer Immunotherapy Trials Network (CITN), Kohrt, H. E. K., Tumeh, P. C., Benson, D., Bhardwaj, N., Brody, J., Formenti, S. C., Fox, B. A., Galon, J., June, C. H., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0118-0 · Cited by 69
“Based on these findings and the expectation that immunotherapy will impact all fields of oncology, Science magazine selected cancer immunotherapy as the breakthrough of 2013 [80].”
Background
Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review
Janiczek-Polewska, M., Szylberg, Ł., Kasperska, A., Kowalewski, A., Parol‐Kulczyk, M., Antosik, P., Radecka, B. S., & Marszałek, A. (2017) · Journal of Immunology Research · doi:10.1155/2017/4861570 · Cited by 70
Nanoscale delivery systems for cancer immunotherapy
Wang, Z., Liu, W., Shi, J., Chen, N., & Fan, C. (2018) · Materials Horizons · doi:10.1039/c7mh00991g · Cited by 68
A novel route to cyclic dominance in voluntary social dilemmas
Guo, H., Song, Z., Geček, S., Li, X., Jusup, M., Perc, M., Moreno, Y., Boccaletti, S., & Wang, Z. (2020) · Journal of The Royal Society Interface · doi:10.1098/rsif.2019.0789 · Cited by 70
Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
Bao, X., Shi, R., Zhao, T., & Wang, Y. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12670 · Cited by 68
“Additionally, immunotherapy serves a promising therapeutic strategy in many cancer types (Bao et al., 2019b; Couzin-Frankel, 2013; Purwar et al., 2012; Schumacher and Schreiber, 2015; Wasiuk et al., 2012) as well.”
Background
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
Amoozgar, Z., & Goldberg, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.007 · Cited by 69
Along the Axis between Type 1 and Type 2 Immunity; Principles Conserved in Evolution from Fish to Mammals
Yamaguchi, T., Takizawa, F., Fischer, U., & Dijkstra, J. M. (2015) · Biology · doi:10.3390/biology4040814 · Cited by 67
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Bullement, A., Latimer, N. R., & Bell‐Gorrod, H. (2018) · Value in Health · doi:10.1016/j.jval.2018.10.007 · Cited by 70
Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
Nejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0599 · Cited by 69
“org Cancer Immunol Res; 7(7) July 2019 1149”
BackgroundInfluential
Current status of immunotherapy
Suzuki, S., Ishida, T., Yoshikawa, K., & Ueda, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv201 · Cited by 66
Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma
Mito, I., Takahashi, H., Kawabata‐Iwakawa, R., Ida, S., Tada, H., & Chikamatsu, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-95718-9 · Cited by 66
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 70
“The immune system plays an essential role in the initiation, progression, and metastasis of cancer [1,2].”
Background
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation
Pan, C., Yang, H., Lu, Y., Hu, S., Wu, Y., He, Q., & Dong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113170 · Cited by 72
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Shariat, S., Badiee, A., Jalali, S. A., Mansourian, M., Yazdani, M., Mortazavi, S. A., & Jaafari, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.016 · Cited by 66
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
Abdin, S. M., Zaher, D. M., Arafa, E. A., & Omar, H. A. (2018) · Cancers · doi:10.3390/cancers10020032 · Cited by 66
“Thus, the inhibition of these checkpoint proteins would activate the immune system against tumors [8].”
Background
Biological Roles of Aberrantly Expressed Glycosphingolipids and Related Enzymes in Human Cancer Development and Progression
Zhuo, D., Li, X., & Guan, F. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00466 · Cited by 66
“Cancer immunotherapy is a highly promising approach that use of the immune system to treat cancer (Couzin-Frankel, 2013).”
Background
The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
Xing, D. T., Siva, S., & Hanna, G. G. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.04.006 · Cited by 66
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 65
Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare
Zhang, R., Gao, X., Bai, H., & Ning, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00538 · Cited by 68
“Immunotherapy is another approach that has shown potential in treating solid cancers and hematopoietic (Couzin-Frankel, 2013).”
Background
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 66
Application of molecular dynamics simulation in self-assembled cancer nanomedicine
Xu, X., Liu, A., Liu, S., Ma, Y., Zhang, X., Zhang, M., Zhao, J.-H., Sun, S., & Sun, X. J. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00386-7 · Cited by 67
“Tumor immunotherapy can effectively eradicate primary and metastatic tumors and inhibit tumor via the anti-tumor immune response produced by the host cells [194, 195].”
Background
Overexpressed oncogenic tumor-self antigens
Bright, R. K., Bright, J. D., & Byrne, J. A. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29475 · Cited by 70
“This promise is now being realized by FDA approval of two of the newest treatments for prostate cancer and melanoma, Sipuleucel T and CTLA-4 blockade.(3,8) Both of these immunotherapies rely on eliciting T cell-mediated immunity which requires antigen recognition and specificity.”
T-Cell Immunotherapy: Looking Forward
Corrigan‐Curay, J., Kiem, H., Baltimore, D., O’Reilly, M., Brentjens, R. J., Cooper, L. J. N., Forman, S. J., Gottschalk, S. M., Greenberg, P. D., Junghans, R. P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.148 · Cited by 65
Preparation, characterization, and transfection efficiency of low molecular weight polyethylenimine-based nanoparticles for delivery of the plasmid encoding CD200 gene
Nouri, F., Sadeghpour, H., Heidari, R., & Dehshahri, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140734 · Cited by 65
Trial watch
Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.29030 · Cited by 64
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
Jiang, L., Su, X., Zhang, T., Yin, X., Zhang, M., Fu, H., Han, H., Sun, Y., Dong, L., Qian, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15839 · Cited by 69
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
Xie, Y., Xiang, Y., Sheng, J., Zhang, D., Yao, X., Yang, Y., & Zhang, X. (2018) · Journal of Immunology Research · doi:10.1155/2018/8740976 · Cited by 62

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks